NeuroMetrix Reports Q4 and Full Year 2019 Financial Results
NeuroMetrix, Inc. (NURO)
Last neurometrix, inc. earnings: 4/20 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.neurometrix.com/investor-relations
Company Research
Source: GlobeNewswire
WOBURN, Mass., Jan. 27, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2019. The Company develops and commercializes diagnostic and therapeutic neurostimulation-based medical devices. The Company has three commercial products. DPNCheck® is a point-of-care diagnostic test for peripheral neuropathies including diabetic peripheral neuropathy (DPN). ADVANCE™ is a point-of-care diagnostic test primarily used for carpal tunnel syndrome. Quell® is a wearable neurostimulation device that is available over-the-counter for symptomatic relief of chronic pain. Q4 2019 Highlights: DPNCheck posted Q4 2019 revenue of $0.9 million, an increase of 51% over the prior year quarter. The improvement came in the US Medicare Advantage market, which was consistent with strong performance of this segment throughout 2019. In the full year 2019, Medicare Advantage revenue growth was 25% over the prio
Show less
Read more
Impact Snapshot
Event Time:
NURO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NURO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NURO alerts
High impacting NeuroMetrix, Inc. news events
Weekly update
A roundup of the hottest topics
NURO
News
- NeuroMetrix, Inc. (NASDAQ: NURO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- NeuroMetrix, Inc. (NASDAQ: NURO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- NeuroMetrix Third Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.66 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- NeuroMetrix Reports Q3 2024 Business HighlightsGlobeNewswire
- NeuroMetrix, Inc. (NASDAQ: NURO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
NURO
Sec Filings
- 11/5/24 - Form 10-Q
- 11/5/24 - Form 4
- 11/5/24 - Form 4
- NURO's page on the SEC website